N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=112 Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
COVID-19
Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale
Phase 4 N=50 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
Increased Risk of SARS-CoV-2 Infection
Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants
Phase 3 N=2,441 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With…
N/A N=820 The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
Covid19
Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
Phase 3 N=1,483 Pre-exposure Prophylaxis for SARS-Coronavirus-2
COVID-19 · Corona Virus Infection · ARDS
Primary: COVID-19-free Survival — 464; 468; 454 Participants
Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
Phase 3 N=9,902 A Study of S-268019 for the Prevention of COVID-19
SARS-CoV-2
Primary: Number of Participants With First Occurrence of SARS-CoV-2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Positive Symptomatic COVID-19 With Onset at Least 14…
N/A N=3,632 Epidemiological Study of the COVID-2019 in Participating Organizations.
Covid19
Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person
Phase 2 N=98 COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
COVID-19 · SARS-CoV 2
Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers
N/A N=9,374 Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings
Intellectual Disability · Developmental Disability · Axis I Diagnosis
Primary: New COVID-19 Group Home Incidence — 1.61; 1.40; 0.16; 0.09 New COVID-19 cases per 100 person-months — p=0.89
Phase 3 N=2,834 Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs) in Primary Vaccination Cohort (PVC):- AZD2816 (4), Booster…
Phase 2 N=256 Study of AZD1222 for the Prevention of COVID-19 in Japan
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
N/A N=215 COVID-19 Risk Reduction Among African American Parishioners
Coronavirus
Primary: Mean Change in the Ability to Implement COVID-19 Health Guidelines Among African American Churches in South Los Angeles 3 Months After Workshop — 3.00000 score on a…
N/A N=7,444 Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Healthy
Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77
Phase 3 N=3,298 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Healthy Participants
Primary: Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP — 7.8; 1.4 Percentage of Participants…
Phase 3 N=829 Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
COVID-19 · Corona Virus Infection · SARS (Severe Acute Respiratory Syndrome)
Primary: Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection — 45; 53 Participants
N/A N=74 Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
HIV-1-infection · Hypertension
Primary: Proportion of Eligible Participants Who Agree to Participate — 74 Participants
Phase 4 N=659 BCG Vaccine for Health Care Workers as Defense Against COVID 19
Coronavirus · Coronavirus Infection · Coronavirus as the Cause of Diseases Classified Elsewhere
Primary: Number of New COVID 19 Infections — 25; 21 Participants
N/A N=172 Addressing COVID-19 Mental Health Problems Among US Veterans
Brief Video-based Intervention · Vignette Based Intervention · Non Intervention Control Arm
Primary: Help Seeking Intention — 7.4; 7.9; 7.3; 8.2 units on a scale — p=0.031
N/A N=2,097 COVID-19 Watch + COVID-19 Pulse
Covid19
Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days
Phase 1 N=185 Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
Phase 2 N=48 Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
Covid19
Primary: Recruitment Feasibility — 46 Participants
Phase 2 N=399 A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
COVID-19
Primary: COVID-19 Prophylaxis — 30; 105 Participants
Phase 2 N=124 Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19)
Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants
Phase 1 N=150 N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Coronavirus · Covid19
Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297
Phase 2 N=132 GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
Pneumonitis · SARS-CoV Infection
Primary: Number of Serious Adverse Events Relative to Treatment Group — 1; 3; 0 participants
Phase 1 N=99 Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Phase 3 N=1,312 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Corona Virus Infection · Acute Respiratory Distress Syndrome · SARS-CoV Infection
Primary: Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline — 49; 58 Participants — p=0.35